Skip to main content
GlaxoSmithKline PLC logo

GlaxoSmithKline PLC — Investor Relations & Filings

Ticker · GSK ISIN · GB00BN7SWP63 LEI · 5493000HZTVUYLO1D793 IL Manufacturing
Open in API
Filings indexed 7,020 across all filing types
Latest filing 2026-05-26 Share Issue/Capital Cha…
Country GB United Kingdom
Listing IL GSK

About GlaxoSmithKline PLC

https://www.gsk.com/en-gb/

GSK plc is a global biopharmaceutical company that unites science, technology, and talent to research, develop, and manufacture medicines and vaccines. The company focuses on preventing and treating disease across four primary therapeutic areas: infectious diseases, HIV, oncology, and immunology/respiratory. Its portfolio consists of specialty medicines and vaccines aimed at addressing significant global health needs. GSK's strategy centers on leveraging its research and development capabilities to deliver new health solutions.

Recent filings

Filing Released Lang Actions
Admission to Trading
Share Issue/Capital Change Classification · 90% confidence The document is an RNS announcement by GSK plc notifying the market that additional ordinary shares have been admitted to trading under an existing block listing admission (Share Save Plan). It provides ISIN, number of shares admitted, total securities, and other details specific to a new share issuance admission. This matches the “Share Issue/Capital Change” category (SHA).
2026-05-26 English
Transaction in Own Shares
Transaction in Own Shares Classification · 98% confidence The document is an RNS announcement titled “Transaction in own shares” detailing GSK plc’s repurchase of ordinary shares, including purchase dates, volumes, prices, treasury holding updates, and regulatory references. This matches the definition for a share buyback report, which aligns with the “Transaction in Own Shares” category (POS).
2026-05-26 English
ADMISSION TO TRADING
Regulatory Filings
2026-05-26 English
TRANSACTION IN OWN SHARES
Regulatory Filings
2026-05-26 English
Q2 2026 Results Date Confirmed - 28 July 2026
Report Publication Announcement Classification · 95% confidence The document is an RNS press release from GSK plc providing the scheduled dates for upcoming quarterly results publications (Q2, Q3, Q4 2026) and related dividend dates. It does not contain actual financial results, rather it announces the timing of future report releases. This matches the “Report Publication Announcement” category (RPA).
2026-05-22 English
Q2 2026 RESULTS DATE CONFIRMED - 28 JULY 2026
Regulatory Filings
2026-05-22 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.